Tags : Taisho

PharmaShots Weekly Snapshot (September 30–October 04, 2019)

1. Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B Published: Oct 03, 2019 | Tags: Arbutus, Discontinue, P-Ia/Ib, Clinical Study, AB-506, Chronic Hepatitis B 2. Janssen’s Niraparib Receives the US FDA’s Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer Published: Oct 03, 2019 | Tags: Janssen, Niraparib, Receives, US, […]Read More

Taisho Signs an Exclusive License Agreement with Moberg Pharma to

Shots: Moberg to receive $5M up front, $50M as development, regulatory & commercial milestone along with supply fees & royalties on sales. Taisho to get exclusive right to develop, register & commercialize MOB-015 in Japan and will fund & conduct development and registration activities in Japan The agreement is the third major agreement for MOB-015, […]Read More

Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Shots: Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B, in all stock transaction with the put option. The transaction is expected to close in H1’19 The focus of the agreement is to allow BMS to emphasize on its portfolio offering treatments in serious diseases and strengthen Taisho’s OTC platform UPSA develops and delivers medicines in multiple therapeutic […]Read More